CUDC-907

DRUG4 trials

Sponsors

Curis, Inc., Dana-Farber Cancer Institute, National Cancer Institute (NCI)

Conditions

Brain TumorDifferentiated Thyroid CancerHigh-grade Serous Ovarian CancerLymphomaNUT Midline CarcinomaNeuroblastomaPoorly Differentiated and Undifferentiated Thyroid CancerRelapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Phase 1

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

CompletedNCT02307240

Curis, Inc.High-grade Serous Ovarian Cancer, NUT Midline Carcinoma, Solid Tumors +1

Start: 2014-11-30End: 2019-05-31Updated: 2019-09-03

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

CompletedNCT02909777

Dana-Farber Cancer InstituteBrain Tumor, Lymphoma, Neuroblastoma +1

Start: 2016-10-01End: 2025-12-01Updated: 2026-02-11

Phase 2

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

CompletedNCT02674750

Curis, Inc.Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Start: 2016-07-31End: 2019-05-28Updated: 2022-04-27

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

TerminatedNCT03002623

National Cancer Institute (NCI)Differentiated Thyroid Cancer, Poorly Differentiated and Undifferentiated Thyroid Cancer, Thyroid Neoplasms

Start: 2016-12-22End: 2018-02-12Updated: 2018-12-21

Related Papers

A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors.

2025-12-01

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

2022-04-12102 citations

Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.

Journal of Clinical Oncology2018-05-205 citations

Prolonged Disease Stabilization and Tolerability in a Nuclear Protein in Testis Midline Carcinoma Patient Treated with Dual Histone Deacetylase and Phosphoinositide 3-Kinase Inhibitor CUDC-907

Case Reports in Clinical Medicine2018-01-015 citations

Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.

Journal of Clinical Oncology2017-05-201 citations

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

Blood2016-12-021 citations